BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Quercetin
,
rs4950928
,
VEGFA
,
glucose metabolic process
,
Ischemia
,
Adipose tissue
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
BRAF
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Cerebellar hemisphere
Cerebellar vermis
Cerebellum
Thalamus lateral nuclei
Prefrontal cortex
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Cardio-facio-cutaneous syndrome
Lentigo
Noonan's syndrome
Hyperpigmentation of skin
Turner syndrome
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Oxyphenisatin Acetate
phensuximide
Maneb
4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo(2,3-d)-pyrimidine-5-carboxamide
Nordihydroguaiaretic Acid
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
TLX3
CBX2
AKT3
DCAF1
ATP5F1B
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.
Computational analysis of natural product B-Raf inhibitors.
Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.
A novel BRAF::PTPRN2 fusion in meningioma: a case report.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Me…
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
ENCOrafenib With Binimetinib in bRAF NSCLC
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trame…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ